Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
1
13%
Ph phase_1
2
25%
Ph phase_4
4
50%
Ph not_applicable
1
13%

Phase Distribution

2

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 4Post-market surveillance
4(50.0%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
Withdrawn1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 44 (50.0%)
N/A1 (12.5%)

Trials by Status

completed563%
withdrawn113%
terminated113%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets

NCT04199624
terminatednot_applicable

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

NCT04333407
completedphase_4

Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS

NCT03238534
completedphase_4

Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis

NCT03086070
unknownphase_4

A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis

NCT03908619
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04199624Phase 1

Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets

Completed
NCT04333407Not Applicable

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

Terminated
NCT03238534Phase 4

Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS

Completed
NCT03086070Phase 4

Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis

Completed
NCT03908619Phase 4

A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis

Unknown
NCT03291249Phase 2

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

Withdrawn
NCT03378960Phase 4

Study to Compare the Bioavailability of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity

Completed
NCT03561233Phase 1

Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8